View ValuationVivesto 향후 성장Future 기준 점검 0/6Vivesto 의 수익과 수익은 각각 연간 122% 및 23% 감소할 것으로 예상됩니다. EPS는 연간 10.6% 만큼 쇠퇴할 것으로 예상됩니다. 자기자본이익률은 3년 후 -30.1% 로 예상됩니다.핵심 정보-23.0%이익 성장률-10.62%EPS 성장률Biotechs 이익 성장33.0%매출 성장률-122.0%향후 자기자본이익률-30.13%애널리스트 커버리지Low마지막 업데이트13 Aug 2026최근 향후 성장 업데이트Price Target Changed • Nov 21Price target decreased by 35% to kr0.24Down from kr0.37, the current price target is provided by 1 analyst. New target price is 67% above last closing price of kr0.14. Stock is down 48% over the past year. The company is forecast to post a net loss per share of kr0.06 next year compared to a net loss per share of kr0.074 last year.Price Target Changed • Nov 16Price target decreased to kr1.05Down from kr6.10, the current price target is provided by 1 analyst. New target price is 62% above last closing price of kr0.65. Stock is down 71% over the past year. The company is forecast to post a net loss per share of kr0.30 next year compared to a net loss per share of kr0.30 last year.Major Estimate Revision • Dec 08Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast increased from kr10.2m to kr16.5m. EPS estimate unchanged from -kr0.40 at last update. Biotechs industry in Sweden expected to see average net income growth of 4.7% next year. Consensus price target of kr5.70 unchanged from last update. Share price rose 11% to kr2.42 over the past week.모든 업데이트 보기Recent updatesNew Risk • Jul 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr41m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr41m free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings are forecast to decline by an average of 27% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (106% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (kr94.1m market cap, or US$9.67m). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (kr50m net loss in 2 years).New Risk • Jun 28New minor risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow. Free cash flow: -kr41m This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings are forecast to decline by an average of 27% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (106% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (kr95.1m market cap, or US$9.77m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-kr41m). Currently unprofitable and not forecast to become profitable over next 2 years (kr50m net loss in 2 years).New Risk • Jun 25New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: kr95.2m (US$9.79m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings are forecast to decline by an average of 23% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (106% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (kr95.2m market cap, or US$9.79m). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (kr63m net loss in 3 years).공고 • Jun 17Vivesto AB Reports Positive Results From Intravenous Cantrixil Pharmacokinetic And Toxicology StudyVivesto AB reported positive results from its exploratory pharmacokinetic (PK) and toxicology study with Cantrixil. The study is the first conducted with Cantrixil administrated intravenously (i.v.) in a larger animal species (dog). The data support continued development of Cantrixil toward a Phase I clinical trial in acute myeloid leukemia (AML) in humans, and a pilot study in dogs with cancer. The study results demonstrate that i.v. Cantrixil was well tolerated at all dose levels, with no adverse findings, no cardiovascular effects, and no signs of local irritation or toxicity at the injection site. Pharmacokinetic parameters, including blood concentration levels and half-life, were consistent with expectations and complement prior preclinical data. In the PK/toxicology study, four dogs received increasing i.v. doses of Cantrixil in three rounds at 2, 5 and 10 mg/kg. The study design and day 7 assessments support the intended once-weekly dosing frequency for both humans and dogs. Cantrixil was well tolerated by all dogs, with no adverse or toxicologically relevant findings. No cardiovascular adverse effects were reported, a particularly important finding as cardiovascular toxicity is a known and often dose-limiting risk for cytotoxic agents. Furthermore, there were no local signs of irritation or toxicity at the injection site. Hematological and clinical biochemistry parameters, which were analyzed before treatment start and 7 days after each treatment administration, a common timepoint for assessing cytotoxic agents, showed no alterations. The pharmacokinetic parameters of Cantrixil, including blood concentration levels, were in line with previous observations from the in vivo study performed in a mouse model of AML earlier last year. Drug half-life was as expected, confirming that the i.v. formulation performs as intended and is consistent with existing preclinical documentation. Together with previous findings, these new results support the continued advancement of Cantrixil toward a Phase I clinical trial in AML in humans, in parallel with continued CMC development to produce clinical trial material. As previously announced, Vivesto is also developing Cantrixil for dogs with cancer, building on its anti-cancer mechanism of action and synergies with the company’s existing veterinary oncology program.New Risk • Feb 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 106% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings are forecast to decline by an average of 14% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (106% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr44m net loss in 2 years). Market cap is less than US$100m (kr96.0m market cap, or US$10.7m).New Risk • Feb 03New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 106% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings are forecast to decline by an average of 14% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (106% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr44m net loss in 2 years). Market cap is less than US$100m (kr98.4m market cap, or US$11.0m).공고 • Jan 24Vivesto AB has completed a Follow-on Equity Offering in the amount of SEK 53.804346 million.Vivesto AB has completed a Follow-on Equity Offering in the amount of SEK 53.804346 million. Security Name: Shares Security Type: Common Stock Securities Offered: 538,043,455 Price\Range: SEK 0.1 Transaction Features: Rights OfferingPrice Target Changed • Nov 21Price target decreased by 35% to kr0.24Down from kr0.37, the current price target is provided by 1 analyst. New target price is 67% above last closing price of kr0.14. Stock is down 48% over the past year. The company is forecast to post a net loss per share of kr0.06 next year compared to a net loss per share of kr0.074 last year.New Risk • Nov 20New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: kr88.0m (US$9.22m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 17% per year for the foreseeable future. Revenue is less than US$1m. Market cap is less than US$10m (kr88.0m market cap, or US$9.22m). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr49m net loss in 2 years). Share price has been volatile over the past 3 months (11% average weekly change).공고 • Nov 20Vivesto AB has filed a Follow-on Equity Offering in the amount of SEK 53.804346 million.Vivesto AB has filed a Follow-on Equity Offering in the amount of SEK 53.804346 million. Security Name: Shares Security Type: Common Stock Securities Offered: 538,043,455 Price\Range: SEK 0.1 Transaction Features: Rights Offering공고 • Nov 08Vivesto AB, Annual General Meeting, May 07, 2026Vivesto AB, Annual General Meeting, May 07, 2026. Location: stockholm SwedenBoard Change • Sep 15Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. No highly experienced directors. Independent Director Pal Ryfors was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.공고 • Apr 08Vivesto AB, Annual General Meeting, May 08, 2025Vivesto AB, Annual General Meeting, May 08, 2025, at 09:00 W. Europe Standard Time. Location: at gustav iii:s boulevard 42, ground floor, se-169 73 solna, Sweden공고 • Apr 01Vivesto AB Reports Positive Cantrixil Results in an Animal Hematological Cancer ModelVivesto AB announced that positive preclinical efficacy data was obtained in an animal model of hematological cancer. The results support continued development of the candidate drug Cantrixil within this indication and are in line with previous positive preclinical data. The experimental trial demonstrates, for the first time, that Cantrixil can reduce tumor growth and increase survival times in a well-established mouse model of hematological cancer. The treatment was well tolerated and safe. With the new positive data, Vivesto is continuing the planning of activities needed to bring Cantrixil into clinical trials and in parallel will investigate opportunities to partner the project in order to optimize the development program.공고 • Jan 16Vivesto AB Receives Approval to Initiate A Dose-Finding Study of Paccal Vet in CatsVivesto AB announced that ethical approval has been obtained from the US Veterinary Review Board Clinical Studies Committee for a planned Paccal Vet dose-finding clinical trial in cats with cancer. The approval authorizes the participating clinical sites to enroll patients in the study. The dose-finding study will initially be conducted at two clinical sites in Washington and Oregon, with the possibility to include more sites as the study progresses. The study will be managed by CASTR Alliance, the contract research organization (CRO) currently running Paccal Vet's pilot clinical trial in dogs with splenic hemangiosarcoma in the US. FDA's Center for Veterinary Medicine, CVM, has previously confirmed that the cat study can be conducted under the existing INAD (Investigational New Animal Drug). The dose-finding study will follow the 3+3 design, a widely used approach to determine the maximum tolerated dose (MTD). A maximum of 12 cats will be included, receiving Paccal Vet treatment in groups of three, with doses escalating for each group until the MTD is identified. This study design ensures patient safety while effectively identifying the appropriate dosage for Paccal Vet administration in cats.공고 • Dec 20Vivesto Strengthens Cantrixil Program with New Preclinical Results and Patent ApplicationVivesto AB, announced that positive results were obtained from preclinical studies with combination treatments within the company’s Cantrixil program, supporting continued development in hematological cancer. Vivesto also announced that a new patent application covering the treatment of hematological cancer with Cantrixil was filed, with the aim to strengthen the IP position. The drug candidate Cantrixil has been evaluated in further combination treatments with other anti-cancer drugs generating new in vitro data in hematological cancer cell lines. The results demonstrate clear positive effects of Cantrixil in combination with other anti-cancer drugs. The positive results confirm previous preclinical efficacy results and support continued development in hematological cancer. New results from hematological cancer models are expected to be presented throughout 2025. Cantrixil has previously shown strong cytotoxic effects at low doses in cell lines derived from patients with hematological cancer. The recently generated data provides important input to the dosing selection and treatment regime in upcoming preclinical and clinical studies.공고 • Jan 30Vivesto's International Patent Application for XR-18 Receives Positive DecisionVivesto AB, announced that the European Patent Office (EPO) has granted a positive approval regarding the patentability of the company's XR-18 technology platform in Vivesto's international patent application (Patent Cooperation Treaty; PCT). The patent application for XR-18 is now in an international phase, which provides the opportunity to apply for patents in countries that are part of the PCT collaboration (157 countries). Vivesto now has two independent assessments that have been positive about the patentability of the XR-18 invention; EPO and earlier from the Swedish Intellectual Property Office (PRV). The company will now evaluate in which countries the company intends to seek protection.공고 • Dec 28Vivesto AB's US Clinical Paccal Vet Trial Receives Approval to Start Patient RecruitmentVivesto AB announced that the US Veterinary Review Board Clinical Studies Committee approved the company's planned Paccal Vet open label, pilot clinical study in dogs with splenic hemangiosarcoma following splenectomy. Clinical sites have been chosen and will be ready to start activities after supply of Paccal Vet (investigational veterinary product, IVP) in January. A planned interim analysis is expected in the second half of 2024. The Paccal Vet development program was discussed with FDA earlier this year. No further Agency approval is required prior to study start. The study is an open label, exploratory indication finding study in dogs with different stages of splenic hemangiosarcoma (HSA) following splenectomy. The study will include 4 treatment cycles of Paccal Vet (paclitaxel micellar) and it is planned to investigate 2 cohorts. Each cohort is planned to include a maximum of 23 patients. The study will be conducted at 6 clinical sites in Washington and Oregon. First patients are expected to be dosed in early 2024 and a planned interim analysis is expected in the second half of 2024. If promising activity in either cohort is shown, the study shall be followed by a pivotal study designed to confirm the initial findings of this pilot study and to gather further evidence on the safety and efficacy of Paccal Vet in dogs with splenic hemangiosarcoma. Vivesto's drug candidate Paccal Vet consists of paclitaxel formulated with the company's proprietary XR-17 technology. Vivesto has previously shown good safety of Paccal Vet in the treatment of various types of cancer in dogs. The absence of the solvent cremophor, to which dogs are particularly sensitive, may reduce the risk of serious side effects and death associated to the treatment. Paccal Vet also does not require the addition of human albumin, which when used in dogs can cause hypersensitivity reactions and reduced treatment effectiveness.공고 • Nov 24Vivesto AB (publ) Announces Composition of Nomination CommitteeIn accordance with the principles for appointing a Nomination Committee, which were adopted at Vivesto AB's Annual General Meeting in 2022, it is hereby announced that the Nomination Committee for the 2024 Annual General Meeting has been appointed, based on the ownership structure as per 30 September 2023. The Nomination Committee for the 2024 Annual General Meeting comprises the following members: Per Arwidsson, appointed by Arwidsro, Håkan Lagerberg, appointed by Mastan AB, and Peter Zonabend, Chairman of the Board of Vivesto. Per Arwidsson has been appointed Chairman of the Nomination Committee.공고 • Nov 18Vivesto AB, Annual General Meeting, May 23, 2024Vivesto AB, Annual General Meeting, May 23, 2024.공고 • Nov 17+ 2 more updatesVivesto AB to Report Nine Months, 2024 Results on Nov 21, 2024Vivesto AB announced that they will report nine months, 2024 results on Nov 21, 2024New Risk • Oct 12New major risk - Revenue and earnings growthEarnings have declined by 16% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 16% per year over the past 5 years. Revenue is less than US$1m (kr3.0m revenue, or US$277k). Minor Risk Market cap is less than US$100m (kr115.1m market cap, or US$10.5m).New Risk • Aug 25New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr84m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr84m free cash flow). Revenue is less than US$1m (kr2.2m revenue, or US$194k). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr145m net loss in 2 years). Market cap is less than US$100m (kr122.7m market cap, or US$11.1m).공고 • Aug 05Vivesto AB Announces Early Termination of Patient Enrollment in the Investigator-Initiated Phase 1B Docetaxel Micellar StudyVivesto AB announced early termination of patient enrollment in the Docetaxel micellar advanced prostate cancer Phase 1b study with the Swiss Group for Clinical Cancer Research (SAKK). The open-label, multicenter, single-stage Phase 1b study has closed its accrual after enrollment of 11 of the planned 18 patients, since Vivesto believes that the data generated will be sufficient ahead of switching into development with a new formulation based on its improved XR-18 micelle technology platform. Docetaxel mousellar has shown good tolerability at doses considered standard for conventional docetaxel formulations, as well as signs of clinical activity. Docetaxel miceLLar has been well received by investigators of the SAKK 67/20 and by participating prostate cancer patients. Vivesto's Docetaxel micellAR is a solvent-free formulation of docetaxel developed to avoid the need for the solubility enhancers in a solvent-based docetaxel and the mandatory high-dose steroid premedication. Patients treated with other existing formulations of docetaxel require steroid administration to avoid certain serious adverse events related to the formulations with solvent. The administration of steroids can lead to marked bone fragility, exacerbated by cancer metastases in the bone, or steroid-related metabolic issues. Vivesto has progressed in the development of its XR-18 drug delivery platform and intends to use this next-generation improved technology in future development of Docetaxel miceller.분석 기사 • Apr 25Will Vivesto (STO:VIVE) Spend Its Cash Wisely?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Reported Earnings • Feb 24Full year 2022 earnings released: kr0.34 loss per share (vs kr0.30 loss in FY 2021)Full year 2022 results: kr0.34 loss per share (further deteriorated from kr0.30 loss in FY 2021). Net loss: kr166.7m (loss widened 26% from FY 2021). Revenue is forecast to grow 48% p.a. on average during the next 2 years, compared to a 21% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 62% per year, which means it is significantly lagging earnings.Reported Earnings • Nov 19Third quarter 2022 earnings released: kr0.14 loss per share (vs kr0.069 loss in 3Q 2021)Third quarter 2022 results: kr0.14 loss per share (further deteriorated from kr0.069 loss in 3Q 2021). Net loss: kr71.7m (loss widened 131% from 3Q 2021). Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 28% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings.공고 • Nov 17+ 3 more updatesVivesto AB to Report Fiscal Year 2023 Results on Feb 23, 2024Vivesto AB announced that they will report fiscal year 2023 results on Feb 23, 2024Price Target Changed • Nov 16Price target decreased to kr1.05Down from kr6.10, the current price target is provided by 1 analyst. New target price is 62% above last closing price of kr0.65. Stock is down 71% over the past year. The company is forecast to post a net loss per share of kr0.30 next year compared to a net loss per share of kr0.30 last year.Reported Earnings • Aug 25Second quarter 2022 earnings releasedSecond quarter 2022 results: Net loss: kr38.5m (loss narrowed 33% from 2Q 2021). Over the next year, revenue is forecast to grow 60%, compared to a 217% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings.분석 기사 • Aug 21Will Vivesto (STO:VIVE) Spend Its Cash Wisely?We can readily understand why investors are attracted to unprofitable companies. For example, although...Reported Earnings • May 26First quarter 2022 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2022 results: kr0.06 loss per share (up from kr0.10 loss in 1Q 2021). Net loss: kr26.5m (loss narrowed 36% from 1Q 2021). Revenue exceeded analyst estimates by 59%. Earnings per share (EPS) also surpassed analyst estimates by 25%. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings.Board Change • Apr 27High number of new and inexperienced directorsThere are 11 new directors who have joined the board in the last 3 years. The company's board is composed of: 11 new directors. 1 experienced director. No highly experienced directors. Independent Director Peter Zonabend is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Reported Earnings • Feb 25Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2021 results: kr0.30 loss per share (up from kr0.47 loss in FY 2020). Net loss: kr132.7m (loss narrowed 37% from FY 2020). Revenue exceeded analyst estimates by 59%. Earnings per share (EPS) missed analyst estimates by 25%. Over the next year, revenue is expected to shrink by 41% compared to a 205% growth forecast for the pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings.Major Estimate Revision • Dec 08Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast increased from kr10.2m to kr16.5m. EPS estimate unchanged from -kr0.40 at last update. Biotechs industry in Sweden expected to see average net income growth of 4.7% next year. Consensus price target of kr5.70 unchanged from last update. Share price rose 11% to kr2.42 over the past week.Recent Insider Transactions • Aug 23Independent Chairman recently bought kr53k worth of stockOn the 19th of August, Anders Harfstrand bought around 20k shares on-market at roughly kr2.66 per share. In the last 3 months, there was an even bigger purchase from another insider worth kr303k. Anders has been a buyer over the last 12 months, purchasing a net total of kr470k worth in shares.이익 및 매출 성장 예측OM:VIVE - 애널리스트 향후 추정치 및 과거 재무 데이터 (SEK Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/2028N/A-53-53-53112/31/2027N/A-40-40-40112/31/2026N/A-31-30-3016/30/20260-32-30-30N/A3/31/2026N/A-33-41-37N/A12/31/2025N/A-34-44-34N/A9/30/2025N/A-36-41-31N/A6/30/2025N/A-39-50-40N/A3/31/2025N/A-40-39-33N/A12/31/2024N/A-40-47-47N/A9/30/20247-93-46-46N/A6/30/20247-99-54-53N/A3/31/20247-117-62-62N/A12/31/20237-129-69-69N/A9/30/20232-284-88-88N/A6/30/20233-340-92-91N/A3/31/20233-351-89-88N/A12/31/20223-357-86-86N/A9/30/202213-140-105-104N/A6/30/202224-99-107-107N/A3/31/202229-118-134-133N/A12/31/202129-133-180-146N/A9/30/2021-184-348-358-324N/A6/30/2021-195-354-378-341N/A3/31/2021-199-376-216-178N/A12/31/20204-210-211-205N/A10/31/2020205-59-19-11N/A7/31/2020205-24-56-47N/A4/30/2020206-11N/A-7N/A1/31/20204-196N/A-187N/A10/31/20196-167N/A-168N/A7/31/20199-210N/A-134N/A4/30/201910-201N/A-119N/A1/31/201914-154N/A-104N/A10/31/201813-153N/A-97N/A7/31/201813-117N/A-103N/A4/30/201812-118N/A-124N/A1/31/201810-128N/A-124N/A10/31/201710-139N/A-144N/A7/31/20178-155N/A-134N/A4/30/20177-160N/A-133N/A1/31/20177-151N/A-145N/A10/31/201616-137N/A-147N/A7/31/201619-139N/A-142N/A4/30/201623-142N/A-128N/A1/31/201626-139N/A-112N/A10/31/201518-141N/A-93N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: VIVE 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 vs 시장: VIVE 향후 3년 동안 수익성이 없을 것으로 예상됩니다.고성장 수익: VIVE 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 대 시장: VIVE 은(는) 내년에 수익이 없을 것으로 예상됩니다.고성장 매출: VIVE 은(는) 내년에 수익이 없을 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: VIVE는 3년 뒤에도 수익성이 없을 것으로 전망됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/08/17 15:44종가2026/08/17 00:00수익2026/06/30연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Vivesto AB는 5명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Camilla OxhamreCarnegie Investment Bank ABKlas PalinDNB Carnegie Commissioned ResearchSusie JanaEdison Investment Research2명의 분석가 더 보기
Price Target Changed • Nov 21Price target decreased by 35% to kr0.24Down from kr0.37, the current price target is provided by 1 analyst. New target price is 67% above last closing price of kr0.14. Stock is down 48% over the past year. The company is forecast to post a net loss per share of kr0.06 next year compared to a net loss per share of kr0.074 last year.
Price Target Changed • Nov 16Price target decreased to kr1.05Down from kr6.10, the current price target is provided by 1 analyst. New target price is 62% above last closing price of kr0.65. Stock is down 71% over the past year. The company is forecast to post a net loss per share of kr0.30 next year compared to a net loss per share of kr0.30 last year.
Major Estimate Revision • Dec 08Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast increased from kr10.2m to kr16.5m. EPS estimate unchanged from -kr0.40 at last update. Biotechs industry in Sweden expected to see average net income growth of 4.7% next year. Consensus price target of kr5.70 unchanged from last update. Share price rose 11% to kr2.42 over the past week.
New Risk • Jul 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr41m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr41m free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings are forecast to decline by an average of 27% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (106% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (kr94.1m market cap, or US$9.67m). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (kr50m net loss in 2 years).
New Risk • Jun 28New minor risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow. Free cash flow: -kr41m This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings are forecast to decline by an average of 27% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (106% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (kr95.1m market cap, or US$9.77m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-kr41m). Currently unprofitable and not forecast to become profitable over next 2 years (kr50m net loss in 2 years).
New Risk • Jun 25New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: kr95.2m (US$9.79m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings are forecast to decline by an average of 23% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (106% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (kr95.2m market cap, or US$9.79m). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (kr63m net loss in 3 years).
공고 • Jun 17Vivesto AB Reports Positive Results From Intravenous Cantrixil Pharmacokinetic And Toxicology StudyVivesto AB reported positive results from its exploratory pharmacokinetic (PK) and toxicology study with Cantrixil. The study is the first conducted with Cantrixil administrated intravenously (i.v.) in a larger animal species (dog). The data support continued development of Cantrixil toward a Phase I clinical trial in acute myeloid leukemia (AML) in humans, and a pilot study in dogs with cancer. The study results demonstrate that i.v. Cantrixil was well tolerated at all dose levels, with no adverse findings, no cardiovascular effects, and no signs of local irritation or toxicity at the injection site. Pharmacokinetic parameters, including blood concentration levels and half-life, were consistent with expectations and complement prior preclinical data. In the PK/toxicology study, four dogs received increasing i.v. doses of Cantrixil in three rounds at 2, 5 and 10 mg/kg. The study design and day 7 assessments support the intended once-weekly dosing frequency for both humans and dogs. Cantrixil was well tolerated by all dogs, with no adverse or toxicologically relevant findings. No cardiovascular adverse effects were reported, a particularly important finding as cardiovascular toxicity is a known and often dose-limiting risk for cytotoxic agents. Furthermore, there were no local signs of irritation or toxicity at the injection site. Hematological and clinical biochemistry parameters, which were analyzed before treatment start and 7 days after each treatment administration, a common timepoint for assessing cytotoxic agents, showed no alterations. The pharmacokinetic parameters of Cantrixil, including blood concentration levels, were in line with previous observations from the in vivo study performed in a mouse model of AML earlier last year. Drug half-life was as expected, confirming that the i.v. formulation performs as intended and is consistent with existing preclinical documentation. Together with previous findings, these new results support the continued advancement of Cantrixil toward a Phase I clinical trial in AML in humans, in parallel with continued CMC development to produce clinical trial material. As previously announced, Vivesto is also developing Cantrixil for dogs with cancer, building on its anti-cancer mechanism of action and synergies with the company’s existing veterinary oncology program.
New Risk • Feb 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 106% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings are forecast to decline by an average of 14% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (106% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr44m net loss in 2 years). Market cap is less than US$100m (kr96.0m market cap, or US$10.7m).
New Risk • Feb 03New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 106% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings are forecast to decline by an average of 14% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (106% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr44m net loss in 2 years). Market cap is less than US$100m (kr98.4m market cap, or US$11.0m).
공고 • Jan 24Vivesto AB has completed a Follow-on Equity Offering in the amount of SEK 53.804346 million.Vivesto AB has completed a Follow-on Equity Offering in the amount of SEK 53.804346 million. Security Name: Shares Security Type: Common Stock Securities Offered: 538,043,455 Price\Range: SEK 0.1 Transaction Features: Rights Offering
Price Target Changed • Nov 21Price target decreased by 35% to kr0.24Down from kr0.37, the current price target is provided by 1 analyst. New target price is 67% above last closing price of kr0.14. Stock is down 48% over the past year. The company is forecast to post a net loss per share of kr0.06 next year compared to a net loss per share of kr0.074 last year.
New Risk • Nov 20New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: kr88.0m (US$9.22m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 17% per year for the foreseeable future. Revenue is less than US$1m. Market cap is less than US$10m (kr88.0m market cap, or US$9.22m). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr49m net loss in 2 years). Share price has been volatile over the past 3 months (11% average weekly change).
공고 • Nov 20Vivesto AB has filed a Follow-on Equity Offering in the amount of SEK 53.804346 million.Vivesto AB has filed a Follow-on Equity Offering in the amount of SEK 53.804346 million. Security Name: Shares Security Type: Common Stock Securities Offered: 538,043,455 Price\Range: SEK 0.1 Transaction Features: Rights Offering
공고 • Nov 08Vivesto AB, Annual General Meeting, May 07, 2026Vivesto AB, Annual General Meeting, May 07, 2026. Location: stockholm Sweden
Board Change • Sep 15Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. No highly experienced directors. Independent Director Pal Ryfors was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
공고 • Apr 08Vivesto AB, Annual General Meeting, May 08, 2025Vivesto AB, Annual General Meeting, May 08, 2025, at 09:00 W. Europe Standard Time. Location: at gustav iii:s boulevard 42, ground floor, se-169 73 solna, Sweden
공고 • Apr 01Vivesto AB Reports Positive Cantrixil Results in an Animal Hematological Cancer ModelVivesto AB announced that positive preclinical efficacy data was obtained in an animal model of hematological cancer. The results support continued development of the candidate drug Cantrixil within this indication and are in line with previous positive preclinical data. The experimental trial demonstrates, for the first time, that Cantrixil can reduce tumor growth and increase survival times in a well-established mouse model of hematological cancer. The treatment was well tolerated and safe. With the new positive data, Vivesto is continuing the planning of activities needed to bring Cantrixil into clinical trials and in parallel will investigate opportunities to partner the project in order to optimize the development program.
공고 • Jan 16Vivesto AB Receives Approval to Initiate A Dose-Finding Study of Paccal Vet in CatsVivesto AB announced that ethical approval has been obtained from the US Veterinary Review Board Clinical Studies Committee for a planned Paccal Vet dose-finding clinical trial in cats with cancer. The approval authorizes the participating clinical sites to enroll patients in the study. The dose-finding study will initially be conducted at two clinical sites in Washington and Oregon, with the possibility to include more sites as the study progresses. The study will be managed by CASTR Alliance, the contract research organization (CRO) currently running Paccal Vet's pilot clinical trial in dogs with splenic hemangiosarcoma in the US. FDA's Center for Veterinary Medicine, CVM, has previously confirmed that the cat study can be conducted under the existing INAD (Investigational New Animal Drug). The dose-finding study will follow the 3+3 design, a widely used approach to determine the maximum tolerated dose (MTD). A maximum of 12 cats will be included, receiving Paccal Vet treatment in groups of three, with doses escalating for each group until the MTD is identified. This study design ensures patient safety while effectively identifying the appropriate dosage for Paccal Vet administration in cats.
공고 • Dec 20Vivesto Strengthens Cantrixil Program with New Preclinical Results and Patent ApplicationVivesto AB, announced that positive results were obtained from preclinical studies with combination treatments within the company’s Cantrixil program, supporting continued development in hematological cancer. Vivesto also announced that a new patent application covering the treatment of hematological cancer with Cantrixil was filed, with the aim to strengthen the IP position. The drug candidate Cantrixil has been evaluated in further combination treatments with other anti-cancer drugs generating new in vitro data in hematological cancer cell lines. The results demonstrate clear positive effects of Cantrixil in combination with other anti-cancer drugs. The positive results confirm previous preclinical efficacy results and support continued development in hematological cancer. New results from hematological cancer models are expected to be presented throughout 2025. Cantrixil has previously shown strong cytotoxic effects at low doses in cell lines derived from patients with hematological cancer. The recently generated data provides important input to the dosing selection and treatment regime in upcoming preclinical and clinical studies.
공고 • Jan 30Vivesto's International Patent Application for XR-18 Receives Positive DecisionVivesto AB, announced that the European Patent Office (EPO) has granted a positive approval regarding the patentability of the company's XR-18 technology platform in Vivesto's international patent application (Patent Cooperation Treaty; PCT). The patent application for XR-18 is now in an international phase, which provides the opportunity to apply for patents in countries that are part of the PCT collaboration (157 countries). Vivesto now has two independent assessments that have been positive about the patentability of the XR-18 invention; EPO and earlier from the Swedish Intellectual Property Office (PRV). The company will now evaluate in which countries the company intends to seek protection.
공고 • Dec 28Vivesto AB's US Clinical Paccal Vet Trial Receives Approval to Start Patient RecruitmentVivesto AB announced that the US Veterinary Review Board Clinical Studies Committee approved the company's planned Paccal Vet open label, pilot clinical study in dogs with splenic hemangiosarcoma following splenectomy. Clinical sites have been chosen and will be ready to start activities after supply of Paccal Vet (investigational veterinary product, IVP) in January. A planned interim analysis is expected in the second half of 2024. The Paccal Vet development program was discussed with FDA earlier this year. No further Agency approval is required prior to study start. The study is an open label, exploratory indication finding study in dogs with different stages of splenic hemangiosarcoma (HSA) following splenectomy. The study will include 4 treatment cycles of Paccal Vet (paclitaxel micellar) and it is planned to investigate 2 cohorts. Each cohort is planned to include a maximum of 23 patients. The study will be conducted at 6 clinical sites in Washington and Oregon. First patients are expected to be dosed in early 2024 and a planned interim analysis is expected in the second half of 2024. If promising activity in either cohort is shown, the study shall be followed by a pivotal study designed to confirm the initial findings of this pilot study and to gather further evidence on the safety and efficacy of Paccal Vet in dogs with splenic hemangiosarcoma. Vivesto's drug candidate Paccal Vet consists of paclitaxel formulated with the company's proprietary XR-17 technology. Vivesto has previously shown good safety of Paccal Vet in the treatment of various types of cancer in dogs. The absence of the solvent cremophor, to which dogs are particularly sensitive, may reduce the risk of serious side effects and death associated to the treatment. Paccal Vet also does not require the addition of human albumin, which when used in dogs can cause hypersensitivity reactions and reduced treatment effectiveness.
공고 • Nov 24Vivesto AB (publ) Announces Composition of Nomination CommitteeIn accordance with the principles for appointing a Nomination Committee, which were adopted at Vivesto AB's Annual General Meeting in 2022, it is hereby announced that the Nomination Committee for the 2024 Annual General Meeting has been appointed, based on the ownership structure as per 30 September 2023. The Nomination Committee for the 2024 Annual General Meeting comprises the following members: Per Arwidsson, appointed by Arwidsro, Håkan Lagerberg, appointed by Mastan AB, and Peter Zonabend, Chairman of the Board of Vivesto. Per Arwidsson has been appointed Chairman of the Nomination Committee.
공고 • Nov 18Vivesto AB, Annual General Meeting, May 23, 2024Vivesto AB, Annual General Meeting, May 23, 2024.
공고 • Nov 17+ 2 more updatesVivesto AB to Report Nine Months, 2024 Results on Nov 21, 2024Vivesto AB announced that they will report nine months, 2024 results on Nov 21, 2024
New Risk • Oct 12New major risk - Revenue and earnings growthEarnings have declined by 16% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 16% per year over the past 5 years. Revenue is less than US$1m (kr3.0m revenue, or US$277k). Minor Risk Market cap is less than US$100m (kr115.1m market cap, or US$10.5m).
New Risk • Aug 25New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr84m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr84m free cash flow). Revenue is less than US$1m (kr2.2m revenue, or US$194k). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr145m net loss in 2 years). Market cap is less than US$100m (kr122.7m market cap, or US$11.1m).
공고 • Aug 05Vivesto AB Announces Early Termination of Patient Enrollment in the Investigator-Initiated Phase 1B Docetaxel Micellar StudyVivesto AB announced early termination of patient enrollment in the Docetaxel micellar advanced prostate cancer Phase 1b study with the Swiss Group for Clinical Cancer Research (SAKK). The open-label, multicenter, single-stage Phase 1b study has closed its accrual after enrollment of 11 of the planned 18 patients, since Vivesto believes that the data generated will be sufficient ahead of switching into development with a new formulation based on its improved XR-18 micelle technology platform. Docetaxel mousellar has shown good tolerability at doses considered standard for conventional docetaxel formulations, as well as signs of clinical activity. Docetaxel miceLLar has been well received by investigators of the SAKK 67/20 and by participating prostate cancer patients. Vivesto's Docetaxel micellAR is a solvent-free formulation of docetaxel developed to avoid the need for the solubility enhancers in a solvent-based docetaxel and the mandatory high-dose steroid premedication. Patients treated with other existing formulations of docetaxel require steroid administration to avoid certain serious adverse events related to the formulations with solvent. The administration of steroids can lead to marked bone fragility, exacerbated by cancer metastases in the bone, or steroid-related metabolic issues. Vivesto has progressed in the development of its XR-18 drug delivery platform and intends to use this next-generation improved technology in future development of Docetaxel miceller.
분석 기사 • Apr 25Will Vivesto (STO:VIVE) Spend Its Cash Wisely?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Reported Earnings • Feb 24Full year 2022 earnings released: kr0.34 loss per share (vs kr0.30 loss in FY 2021)Full year 2022 results: kr0.34 loss per share (further deteriorated from kr0.30 loss in FY 2021). Net loss: kr166.7m (loss widened 26% from FY 2021). Revenue is forecast to grow 48% p.a. on average during the next 2 years, compared to a 21% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 62% per year, which means it is significantly lagging earnings.
Reported Earnings • Nov 19Third quarter 2022 earnings released: kr0.14 loss per share (vs kr0.069 loss in 3Q 2021)Third quarter 2022 results: kr0.14 loss per share (further deteriorated from kr0.069 loss in 3Q 2021). Net loss: kr71.7m (loss widened 131% from 3Q 2021). Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 28% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings.
공고 • Nov 17+ 3 more updatesVivesto AB to Report Fiscal Year 2023 Results on Feb 23, 2024Vivesto AB announced that they will report fiscal year 2023 results on Feb 23, 2024
Price Target Changed • Nov 16Price target decreased to kr1.05Down from kr6.10, the current price target is provided by 1 analyst. New target price is 62% above last closing price of kr0.65. Stock is down 71% over the past year. The company is forecast to post a net loss per share of kr0.30 next year compared to a net loss per share of kr0.30 last year.
Reported Earnings • Aug 25Second quarter 2022 earnings releasedSecond quarter 2022 results: Net loss: kr38.5m (loss narrowed 33% from 2Q 2021). Over the next year, revenue is forecast to grow 60%, compared to a 217% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings.
분석 기사 • Aug 21Will Vivesto (STO:VIVE) Spend Its Cash Wisely?We can readily understand why investors are attracted to unprofitable companies. For example, although...
Reported Earnings • May 26First quarter 2022 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2022 results: kr0.06 loss per share (up from kr0.10 loss in 1Q 2021). Net loss: kr26.5m (loss narrowed 36% from 1Q 2021). Revenue exceeded analyst estimates by 59%. Earnings per share (EPS) also surpassed analyst estimates by 25%. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings.
Board Change • Apr 27High number of new and inexperienced directorsThere are 11 new directors who have joined the board in the last 3 years. The company's board is composed of: 11 new directors. 1 experienced director. No highly experienced directors. Independent Director Peter Zonabend is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Reported Earnings • Feb 25Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2021 results: kr0.30 loss per share (up from kr0.47 loss in FY 2020). Net loss: kr132.7m (loss narrowed 37% from FY 2020). Revenue exceeded analyst estimates by 59%. Earnings per share (EPS) missed analyst estimates by 25%. Over the next year, revenue is expected to shrink by 41% compared to a 205% growth forecast for the pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings.
Major Estimate Revision • Dec 08Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast increased from kr10.2m to kr16.5m. EPS estimate unchanged from -kr0.40 at last update. Biotechs industry in Sweden expected to see average net income growth of 4.7% next year. Consensus price target of kr5.70 unchanged from last update. Share price rose 11% to kr2.42 over the past week.
Recent Insider Transactions • Aug 23Independent Chairman recently bought kr53k worth of stockOn the 19th of August, Anders Harfstrand bought around 20k shares on-market at roughly kr2.66 per share. In the last 3 months, there was an even bigger purchase from another insider worth kr303k. Anders has been a buyer over the last 12 months, purchasing a net total of kr470k worth in shares.